DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL

NCT03620578 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

97

Enrollment

OTHER

Sponsor class

Conditions

Non Hodgkin Lymphoma
Lymphoma, B-Cell
High-grade B-cell Lymphoma
MYC Translocation
BCL-2 Translocation

Interventions

DRUG: DA-EPOCH-R followed by Nivolumab

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland